In this randomised non-inferiority phase 3 trial , done in seven radiotherapy centres in the Netherlands , we enrolled intermediate-risk or high-risk patients aged between 44 and 85 years with histologically confirmed stage T1b-T4 NX-0MX-0 prostate cancer , a PSA concentration of 60 ng/mL or lower , and WHO performance status of 0-2 .